Episode Details

Entegris, Inc. (ENTG) Q2 2026 — Reported August 4, 2026 BEFORE the US open for the fiscal second quarter ENDED JUNE 27, 2026 (a 13-week quarter - not June 30). Revenue $883.2M, +11.5% YoY and +8.8% sequential, beating the ~$835.8M FactSet consensus by $47.4M or 5.7%. Non-GAAP diluted EPS $0.93 vs $0.66 (+40.9%); GAAP EPS $0.61 vs $0.35 (+74.3%). GAAP gross margin 47.6% (+320bps), GAAP operating margin 18.6% (+520bps), adjusted operating margin 24.5% (from 20.9%), adjusted EBITDA margin 28.4%. Segments: Advanced Purity Solutions $514.6M (+17.0%, adj. margin 30.3% from 24.1%); Materials Solutions $371.3M (+4.6%, adj. margin 20.9% DOWN from 21.3%). Q3 2026 guidance: sales $905-935M (midpoint +14.0% YoY), non-GAAP EPS $0.96-1.04, adjusted EBITDA margin 28.0-29.0%. NO full-year guidance was given. Shares closed the prior regular session at $125.20 (+5.17%) BEFORE the release; the reaction session had not closed when this episode was recorded, with ENTG trading up roughly 8.6% at $135.92. The stock is 32% below its $184.00 closing high of June 22, 2026 and 82% above its $68.80 closing low of November 20, 2025. The fact that makes this quarter interesting: Entegris now reports TWO segments, not the three most write-ups still use. Materials Solutions - the CMP slurries, deposition chemistries and implant gases that a wafer consumes whether or not anybody buys a tool, and therefore the segment that IS the content-per-wafer thesis - grew 4.6% with its adjusted margin going DOWN, to 20.9% from 21.3%. Advanced Purity Solutions, which sells into fab construction and expansion as well as production, grew 17.0% with its adjusted margin up 620 basis points to 30.3%. The secular half is the laggard; the cyclical half carried the print. Across five quarters Materials Solutions has gone $341M, $355M, $349M, $362M, $351M, $371M - nine percent of growth in the strongest capital cycle since 2021. Two more things almost nobody flagged. FIRST, the depreciation line fell $16.9M year over year (from $51.3M to $34.4M, -33%) while operating income rose $58.5M - so 29% of the entire operating profit increase is a non-cash accounting tailwind, not operating leverage. SECOND, first-half R&D was CUT 6.5% to $158.1M (10.8% of sales down to 9.3%) while SG&A rose 11.8%, in a company whose thesis is a strong innovation engine winning content at advanced nodes. THE CALL: AVOID (3/5, A REAL RECOVERY, ALREADY PAID FOR TWICE OVER) — base-case value ~$95.0 vs ~$125.2 today. KEY METRICS: - CALL: AVOID 3/5 - fair value ~$95 vs the $125.20 close (about -24%), and below the LOWEST price target on Wall Street ($115). This is NOT a call against the business or the quarter, both of which were good; it is a call on a share price that ran 167% (from $68.80 on Nov 20 2025 to $184.00 on Jun 22 2026) BEFORE these numbers arrived. We value the ENTERPRISE because debt is a third of the story. Base unlevered free cash flow = ~$540M FY2026E reported FCF (H1 actual was $263.8M) plus ~$155M of after-tax net interest less ~$45M for a cash tax rate normalising from H1's 8.6% toward the 16.2% non-GAAP rate = ~$650M. Grow that 17%/14%/12%/10%/9%, then 6% for five more years, then 3% forever, discounted at 9.25% for a business carrying 3.35x net leverage into a cyclical end market: PV of 2027-2036 FCF $7,084M + PV of terminal value $10,600M = enterprise value $17,685M, less $3,102M net debt = $14,582M equity / 153.6M diluted shares = ~$95. Bear $46, bull $129; probability-weighted 25/50/25 = ~$91. - REVERSE DCF - THE WHOLE ARGUMENT: at $125.20 the market capitalisation is ~$19.2B and enterprise value ~$22.3B - 24.1x trailing adjusted EBITDA of $925.6M and 34.4x our $650M base cash flow. To justify that at 9.25% you need roughly 16% unlevered free cash flow growth for five years and then 9%. The Q3 guide implies +14% revenue at the hottest point of the cycle, and the segment that is supposed to deliver the secular growth grew 4.6%. Note the robustness check: even at a friendly 8.5% discount